FDA OKs dupilumab for treatment of eosinophilic esophagitis in children as young as one year of age

Regeneron Pharmaceuticals and Sanofi today announced that the FDA has approved dupilumab (Dupixent) for the treatment of pediatric patients ages 1 to 11 years, weighing ≥15 kg, with eosinophilic esophagitis (EoE). This approval, which was based on results from the phase 3 EoE KIDS trial, expands the initial approval for EoE in patients ages 12 years and older, weighing ≥40 kg.